Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Intravascular large B-cell lymphoma (IVLBCL) is a very rare form of diffuse large B-cell lymphoma characterized by the selective growth of lymphoma cells within the lumina of small blood vessels (especially the capillaries) that most often presents with a wide range of clinical manifestations (as potentially any tissue can be involved), with patients from Western countries more frequently manifesting with neurological and cutaneous symptoms while patients from Asian countries more frequently displaying hepatosplenomegaly and thrombocytopenia. IVLBCL is characterized by an absence of lymphadenopathy, an aggressive clinical course and a poor prognosis.
Biomarker and diagnostic research for intravascular large B-cell lymphoma has been reported in the published literature.
6 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, biologic therapy, other interventions, and procedural interventions. Pipeline includes 6 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05507541](https://clinicaltrials.gov/study/NCT05507541) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:55 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
PHASE2 |
Mayo Clinic |
UNKNOWN |
[NCT03038672](https://clinicaltrials.gov/study/NCT03038672) | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | PHASE2 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT06834373](https://clinicaltrials.gov/study/NCT06834373) | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | PHASE2 | Mayo Clinic | RECRUITING |
[NCT06736613](https://clinicaltrials.gov/study/NCT06736613) | A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma | PHASE2 | Memorial Sloan Kettering Cancer Center | UNKNOWN |
[NCT05202782](https://clinicaltrials.gov/study/NCT05202782) | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | PHASE2 | Northwestern University | ACTIVE_NOT_RECRUITING |
134 publications have been identified in PubMed for intravascular large B-cell lymphoma. Research spans Case Report / Case Series (71%), Diagnostic / Biomarker (8%), and Review / Meta-Analysis (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 95 | 71% |
Testing and diagnosis research | 11 | 8% |
Research summaries | 9 | 7% |
Clinical study results | 6 | 4% |
New treatment approaches | 6 | 4% |
Disease patterns and progression | 5 | 4% |
Other research | 1 | 1% |
Laboratory research | 1 | 1% |
Ozawa T (2026). [PMID: 42001673](https://pubmed.ncbi.nlm.nih.gov/42001673/). *Respir Investig*. [Case Report / Case Series]
Kefeli M (2026). [PMID: 41961025](https://pubmed.ncbi.nlm.nih.gov/41961025/). *Mayo Clin Proc*. [Case Report / Case Series]
Otsuka K (2026). [PMID: 41127470](https://pubmed.ncbi.nlm.nih.gov/41127470/). *Radiol Case Rep*. [Case Report / Case Series]
Wu Q (2026). [PMID: 42027642](https://pubmed.ncbi.nlm.nih.gov/42027642/). *Oncol Lett*. [Case Report / Case Series]
Schukow C (2026). [PMID: 36944007](https://pubmed.ncbi.nlm.nih.gov/36944007/). *Unknown Journal*. [Review / Meta-Analysis]
Nakajima Y (2026). [PMID: 42178256](https://pubmed.ncbi.nlm.nih.gov/42178256/). *Intern Med*. [Case Report / Case Series]
Zheng Z (2026). [PMID: 41788981](https://pubmed.ncbi.nlm.nih.gov/41788981/). *Front Oncol*. [Case Report / Case Series]
García CR (2026). [PMID: 41872720](https://pubmed.ncbi.nlm.nih.gov/41872720/). *Eur J Haematol*. [Epidemiology / Natural History]
Avivi I (2026). [PMID: 41816813](https://pubmed.ncbi.nlm.nih.gov/41816813/). *Haematologica*. [Gene Therapy / Novel Therapeutics]
Wang L (2026). [PMID: 41836964](https://pubmed.ncbi.nlm.nih.gov/41836964/). *Front Med (Lausanne)*. [Case Report / Case Series]
AI-curated news mentioning intravascular large B-cell lymphoma
Updated Mar 23, 2026
A recent study highlights intravascular large B-cell lymphoma as a condition that can mimic interstitial lung disease due to its prominent neo-angiogenesis. This discovery may aid in better diagnosis and understanding of the disease's presentation.
A study published in PubMed details clinical and histopathological findings from six cases of intravascular large B-cell lymphoma identified among 161 skin biopsy cases. This research contributes to the understanding of this rare lymphoma subtype.